PMID- 37692282 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230915 IS - 2769-6456 (Electronic) IS - 2769-6456 (Linking) VI - 2 IP - 2 DP - 2023 Jun TI - Anti-HIV Drugs Reduce Risk of Prediabetes and Progression to Type 2 Diabetes in HIV-Infected Patients. LID - e37 [pii] LID - 10.1002/mef2.37 [doi] AB - The aim of this study was to investigate whether the use of nucleoside reverse transcriptase inhibitors (NRTIs) impacts the incidence of prediabetes or type 2 diabetes mellitus (T2DM) or the progression from prediabetes to T2DM in people living with HIV (PLWH). We conducted a retrospective cohort study using the U.S. Veterans Health Administration database among adult patients with an HIV diagnosis from the year 2000 until 2021 to determine the incidence of prediabetes and further progression to T2DM among NRTI exposed and unexposed patients. A multistate model was used to evaluate progression from normoglycemia to prediabetes and then to T2DM, and covariate adjustment with the Cox proportional hazards model was used to estimate the hazard ratios. Among 32,240 veterans diagnosed with HIV, prediabetes and T2DM were observed among 20.2% and 20.7% of patients, respectively. Among those diagnosed with prediabetes, 31.8% progressed to T2DM. Patients exposed to NRTIs at any time (86.6%), had a reduced risk of prediabetes [HR 0.50 (0.47-0.53 95% CI)] and among prediabetics, a lower risk of progression to T2DM [HR 0.73 (0.63-0.85 95% CI)] when compared to patients who never used NRTIs. In summary, NRTIs may reduce the risk of developing prediabetes and the progression from prediabetes to T2DM in PLWH. FAU - Magagnoli, Joseph AU - Magagnoli J AD - Dorn Research Institute, Columbia VA Health Care System, Columbia, SC 29209. AD - Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208. FAU - Pereira, Felipe AU - Pereira F AD - Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Departamento de Oftalmologia e Ciencias Visuais, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo 04023-062, Brazil. FAU - Narendran, Siddharth AU - Narendran S AD - Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Aravind Eye Hospital System, Madurai 625020, India. FAU - Huang, Peirong AU - Huang P AD - Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908. FAU - Cummings, Tammy AU - Cummings T AD - Dorn Research Institute, Columbia VA Health Care System, Columbia, SC 29209. AD - Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208. FAU - Hardin, James W AU - Hardin JW AD - Dorn Research Institute, Columbia VA Health Care System, Columbia, SC 29209. AD - Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, SC 29208. FAU - Nguyen, Joseph AU - Nguyen J AD - Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908. FAU - Sutton, S Scott AU - Sutton SS AD - Dorn Research Institute, Columbia VA Health Care System, Columbia, SC 29209. AD - Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, SC 29208. FAU - Ambati, Jayakrishna AU - Ambati J AD - Center for Advanced Vision Science, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908. AD - Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22908. LA - eng GR - R01 AG078892/AG/NIA NIH HHS/United States GR - R01 EY028027/EY/NEI NIH HHS/United States GR - R01 DA054992/DA/NIDA NIH HHS/United States GR - R01 EY029799/EY/NEI NIH HHS/United States GR - R01 EY031039/EY/NEI NIH HHS/United States PT - Journal Article DEP - 20230403 PL - Australia TA - MedComm Futur Med JT - MedComm - Future medicine JID - 9918557782506676 PMC - PMC10489210 MID - NIHMS1876272 OTO - NOTNLM OT - HIV OT - NRTI OT - T2DM OT - database OT - inflammasome OT - prediabetes OT - retrospective COIS- J.A. has received support from the UVA Strategic Investment Fund and National Institutes of Health (NIH) grants (R01EY028027, R01EY029799, R01EY031039, R01AG082108). S.S.S., J.M., T.H.C. are supported by NIH grant R01DA054992 and the South Carolina Center for Rural and Primary Healthcare for projects unrelated to this study. J.A. is a co-founder of DiceRx, iVeena Holdings, iVeena Delivery Systems and Inflammasome Therapeutics, and, unrelated to this work, he has been a consultant for Allergan, Boehringer- Ingelheim, Janssen, Olix Pharmaceuticals, Retinal Solutions, and Saksin LifeSciences unrelated to this work. J.W.H. has received consulting fees from Celgene Corporation unrelated to this work. S.S.S has received research grants from Boehringer Ingelheim, Coherus BioSciences, Alexion Pharmaceuticals, and EMD Serono, all for projects unrelated to study. J.A., S.N., and F.P. are named as inventors on patent applications filed by the University of Virginia or the University of Kentucky. EDAT- 2023/09/11 06:42 MHDA- 2023/09/11 06:43 PMCR- 2024/06/01 CRDT- 2023/09/11 04:35 PHST- 2024/06/01 00:00 [pmc-release] PHST- 2023/09/11 06:43 [medline] PHST- 2023/09/11 06:42 [pubmed] PHST- 2023/09/11 04:35 [entrez] AID - e37 [pii] AID - 10.1002/mef2.37 [doi] PST - ppublish SO - MedComm Futur Med. 2023 Jun;2(2):e37. doi: 10.1002/mef2.37. Epub 2023 Apr 3.